行情

ONCE

ONCE

Spark
NASDAQ

实时行情|Nasdaq Last Sale

110.81
0.00
0.00%
已收盘, 16:50 11/15 EST
开盘
110.60
昨收
110.81
最高
111.03
最低
110.30
成交量
28.74万
成交额
--
52周最高
114.20
52周最低
34.53
市值
42.69亿
市盈率(TTM)
-16.9284
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ONCE 新闻

  • Best-Performing Small-Cap Stocks YTD: November 2019
  • Seeking Alpha - Article.4天前
  • Merger Arbitrage Analysis And Spread Performance - November 03, 2019
  • Seeking Alpha - Article.6天前
  • 7 Philadelphia-area companies make Deloitte fastest-growing list
  • American City Business Journals.6天前
  • Here's Why You Should Add BioMarin Pharmaceutical To Your Portfolio
  • Seeking Alpha - Article.11/04 14:03

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ONCE 简况

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.
展开

Webull提供Spark Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。